We evaluated the efficacy and safety of tacrolimus in patients receiving glucocorticoid therapy for lupus nephritis. Patients with persistent nephritis were randomized to receive 28 weeks of double-blind treatment with tacrolimus (3 mg/day) or placebo. The primary endpoint was the change in the lupus nephritis disease activity index (LNDAI) calculated from scores for daily urinary protein excre...

Purpose: The present study was designed to determine the effect ratio of CYP3A5 on the metabolism of tacrolimus that is used as an immunosuppressant for tissue transplantation. Methods: To determine the role of CYP3A4 and CYP3A5 on tacrolimus metabolism, rats were divided into five groups as: group 1 (control group, tacrolimus only 1 mg/kg i.v.), group 2 (pretreated with ritonavir 5 mg/kg, i.v....

Though tacrolimus-induced nephrotoxicity and hyperkalemia are well known, severe symptomatic hyponatremia is not commonly documented with its use. Here, we report a case of severe symptomatic hyponatremia in a renal transplant recipient on tacrolimus despite normal tacrolimus trough level. All other potential causes of hyponatremia were ruled out in this patient. This case highlights an uncommo...

Kim et al [1] showed interesting results that tacrolimus and low-dose prednisolone therapy induced complete remission rapidly and effectively in adult patients with minimal change disease (MCD). MCD has been regarded as an immunological disorder. Recent works, however, have dramatically enhanced the understanding of podocyte biology, which may be the mainstay involved in the pathogenesis of MCD...

BACKGROUND AND OBJECTIVE The association between the CYP3A4*1B single nucleotide polymorphism (SNP) and tacrolimus pharmacokinetics in different studies is controversial. Therefore, a meta-analysis was employed to evaluate the correlation between the CYP3A4*1B genetic polymorphism and tacrolimus pharmacokinetics at different post-transplantation times in adult renal transplant recipients. MET...

Tacrolimus (FK 506) is a macrolactam derivative with immunomodulatory and anti-inflammatory activity. Topical tacrolimus 0.03% has been used for inflammatory conditions of the anterior segment. This article adds to the literature on the off-license application of tacrolimus ointment, by describing the safe and effective use of the higher strength of 0.1% topical tacrolimus skin ointment in four...

OBJECTIVE To explore the effect of additional administration of tacrolimus to rheumatoid arthritis patients treated with biologics, in whom the effect of biologics is unsatisfactory. METHODS Tacrolimus was administered if the effect of biologics was unsatisfactory for 24 weeks at least in terms of laboratory data or DAS28 level: ESR, CRP level and DAS28 level were not below 15 mm/h, 0.2 mg/dl...

Adult and pediatric patients (n = 347) with atopic dermatitis enrolled in three multicenter, randomized, 6-week studies who had previously used steroids were analyzed to examine the null hypothesis that improvement in atopic dermatitis initiated after prior treatment with steroids eliminates any subsequent treatment differences between tacrolimus ointment and pimecrolimus cream. Of these patien...

Posterior reversible encephalopathy syndrome is a well-known complication of treatment by tacrolimus. We report 2 cases of lung transplant recipients treated with tacrolimus who developed cerebral microbleeds on T2∗-weighted sequences in the acute setting of posterior reversible encephalopathy syndrome. Cerebral microbleeds may be a marker of tacrolimus-induced vasculopathy that may be detected...

TACROLIMUS (FK506) is being used as immunosuppressant in solid organ transplantation. However, its nephrotoxic and neurotoxic effects are well recognized. Recently reversible hypertrophic cardiomyopathy under tacrolimus has been described in five children. 1 In order to evaluate myocardial toxicity of the drug. we examined the cardiac findings at autopsy in adults and children following primary...